Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.52 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972802 | 0.88 | KDM4E (0.67) | MAPTTP53KDM4EGAAGLA | |
| SCHEMBL974653 | 0.86 | VKORC1 (0.56) | MAPTTP53KDM4EGAAGLA | |
| SCHEMBL961165 | 0.85 | TP53 (0.49) | MAPTTP53KDM4EGAAGLA | |
| SCHEMBL971877 | 0.82 | MAP2K1 (0.63) | MAPTKDM4EGAAGLAMAP2K1 | |
| SCHEMBL5649508 | 0.81 | TP53 (0.53) | MAPTTP53KDM4EGAAGLA | |
| SCHEMBL959616 | 0.81 | MAP2K1 (0.68) | MAPTTP53KDM4EGAAGLA | |
| SCHEMBL2249678 | 0.80 | MAP2K1 (0.82) | MAP2K1RAF1 | |
| SCHEMBL9211053 | 0.79 | MCL1 (0.63) | MAPTTP53KDM4EGAAGLA | |
| SCHEMBL14249949 | 0.78 | MAP2K1 (0.54) | MAPTTP53KDM4EGAAGLA | |
| SCHEMBL962318 | 0.77 | MAP2K1 (0.60) | MAPTTP53KDM4EGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994318-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7709664-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7026491-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20060020138-A1 | Coumarin derivatives useful as TNFalpha inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050014705-A1 | Coumarin derivatives useful as tnf alpha inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2002008217-A2 | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014705-A1 | Coumarin derivatives useful as tnf alpha inhibitors | TNF, NFKBIA, TNFRSF1A | MAPT 3071/4885TP53 1082/4885KDM4E 4511/4885 |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | MAPT 3170/4885TP53 1276/4885KDM4E 4508/4885 |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | MAPT 3170/4885TP53 1276/4885KDM4E 4508/4885 |
| US-20060020138-A1 | Coumarin derivatives useful as TNFalpha inhibitors | TNF, NFKBIA, TNFRSF1A | MAPT 3488/4885TP53 1564/4885KDM4E 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.